Stock Events

Stock Events

Corcept Therapeutics 

$59.85
130
-$0.37-0.61% Today

Statistics

Day High
60.8
Day Low
59.03
52W High
90.32
52W Low
32.15
Volume
31,771,939
Avg. Volume
-
Mkt Cap
6.37B
P/E Ratio
172.06
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.3
-0.06
0.18
0.43
Expected EPS
0.011651
Actual EPS
N/A

Financials

13.09%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
1.52BRevenue
199.3MNet Income

Analyst Ratings

86.25Average Price Target
The highest estimate is 110.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
80%
Hold
20%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CORT. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap381.1B
AbbVie competes in the pharmaceuticals space, focusing on therapies that could directly compete with Corcept's treatments in endocrine and metabolic diseases.
Pfizer
PFE
Mkt Cap147.62B
Pfizer operates in various therapeutic areas, including endocrinology, potentially competing with Corcept's hormone-related therapies.
Merck
MRK
Mkt Cap302.33B
Merck is involved in developing medications for a wide range of conditions, including those that could compete with Corcept's focus areas.
Bristol-Myers Squibb
BMY
Mkt Cap121.42B
Bristol Myers Squibb develops drugs in multiple therapeutic areas, including those that could compete with Corcept's products in hormonal and metabolic diseases.
Novartis
NVS
Mkt Cap290.05B
Novartis offers a broad portfolio of drugs, including treatments for endocrine disorders, directly competing with Corcept's market.
AMGEN
AMGN
Mkt Cap183.12B
Amgen focuses on innovative therapeutics, including endocrine and metabolic disorders, which could compete with Corcept's therapies.
Gilead Sciences
GILD
Mkt Cap166.82B
Gilead Sciences, known for its work in antiviral drugs, also explores treatments in other areas that could compete with Corcept's focus on metabolic and endocrine disorders.
Regeneron Pharmaceuticals
REGN
Mkt Cap66.98B
Regeneron Pharmaceuticals focuses on developing drugs for a wide range of diseases, including potential competition in the endocrine and metabolic disorder space.
Vertex Pharmaceuticals
VRTX
Mkt Cap110.28B
Vertex Pharmaceuticals engages in creating treatments for serious diseases, potentially including those that compete with Corcept's niche in hormonal therapies.

About

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Show more...
CEO
Dr. Joseph K. Belanoff M.D.
Employees
500
Country
United States
ISIN
US2183521028

Listings

MI
IT
1CORT.MI
STU
DE
HTD.STU
MU
DE
HTD.MU
XNAS
US
CORT

0 Comments

Share your thoughts

FAQ

What is Corcept Therapeutics stock price today?▼
The current price of CORT is $59.85 USD — it has decreased by -0.61% in the past 24 hours. Watch Corcept Therapeutics stock price performance more closely on the chart.
What is Corcept Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Corcept Therapeutics stocks are traded under the ticker CORT.
Is Corcept Therapeutics stock price growing?▼
CORT stock has risen by +2.69% compared to the previous week, the month change is a +29.8% rise, over the last year Corcept Therapeutics has showed a -24.03% decrease.
What is Corcept Therapeutics market cap?▼
Today Corcept Therapeutics has the market capitalization of 6.37B
When is the next Corcept Therapeutics earnings date?▼
Corcept Therapeutics is going to release the next earnings report on August 05, 2026.
What were Corcept Therapeutics earnings last quarter?▼
CORT earnings for the last quarter are -0.3 USD per share, whereas the estimation was -0.11 USD resulting in a -172.26% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Corcept Therapeutics revenue for the last year?▼
Corcept Therapeutics revenue for the last year amounts to 1.52B USD.
What is Corcept Therapeutics net income for the last year?▼
CORT net income for the last year is 199.3M USD.
How many employees does Corcept Therapeutics have?▼
As of May 26, 2026, the company has 500 employees.
In which sector is Corcept Therapeutics located?▼
Corcept Therapeutics operates in the Health & Wellness sector.
When did Corcept Therapeutics complete a stock split?▼
Corcept Therapeutics has not had any recent stock splits.
Where is Corcept Therapeutics headquartered?▼
Corcept Therapeutics is headquartered in Redwood City, United States.